IBDEI1JN ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24679,1,3,0)
 ;;=3^Pyelonephritis,Chronic,Unspec
 ;;^UTILITY(U,$J,358.3,24679,1,4,0)
 ;;=4^N11.9
 ;;^UTILITY(U,$J,358.3,24679,2)
 ;;=^5015574
 ;;^UTILITY(U,$J,358.3,24680,0)
 ;;=N20.9^^107^1208^116
 ;;^UTILITY(U,$J,358.3,24680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24680,1,3,0)
 ;;=3^Urinary Calculus,Unspec
 ;;^UTILITY(U,$J,358.3,24680,1,4,0)
 ;;=4^N20.9
 ;;^UTILITY(U,$J,358.3,24680,2)
 ;;=^5015610
 ;;^UTILITY(U,$J,358.3,24681,0)
 ;;=R97.20^^107^1208^29
 ;;^UTILITY(U,$J,358.3,24681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24681,1,3,0)
 ;;=3^Elevated PSA
 ;;^UTILITY(U,$J,358.3,24681,1,4,0)
 ;;=4^R97.20
 ;;^UTILITY(U,$J,358.3,24681,2)
 ;;=^334262
 ;;^UTILITY(U,$J,358.3,24682,0)
 ;;=N52.36^^107^1208^34
 ;;^UTILITY(U,$J,358.3,24682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24682,1,3,0)
 ;;=3^Erectile Dysfunction After Interstitial Seed Therapy
 ;;^UTILITY(U,$J,358.3,24682,1,4,0)
 ;;=4^N52.36
 ;;^UTILITY(U,$J,358.3,24682,2)
 ;;=^5138933
 ;;^UTILITY(U,$J,358.3,24683,0)
 ;;=N52.37^^107^1208^35
 ;;^UTILITY(U,$J,358.3,24683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24683,1,3,0)
 ;;=3^Erectile Dysfunction After Prostate Ablative Therapy
 ;;^UTILITY(U,$J,358.3,24683,1,4,0)
 ;;=4^N52.37
 ;;^UTILITY(U,$J,358.3,24683,2)
 ;;=^5138934
 ;;^UTILITY(U,$J,358.3,24684,0)
 ;;=N52.35^^107^1208^36
 ;;^UTILITY(U,$J,358.3,24684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24684,1,3,0)
 ;;=3^Erectile Dysfunction After Radiation Therapy
 ;;^UTILITY(U,$J,358.3,24684,1,4,0)
 ;;=4^N52.35
 ;;^UTILITY(U,$J,358.3,24684,2)
 ;;=^5138932
 ;;^UTILITY(U,$J,358.3,24685,0)
 ;;=R31.21^^107^1208^56
 ;;^UTILITY(U,$J,358.3,24685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24685,1,3,0)
 ;;=3^Hematuria,Microscopic,Asymptomatic
 ;;^UTILITY(U,$J,358.3,24685,1,4,0)
 ;;=4^R31.21
 ;;^UTILITY(U,$J,358.3,24685,2)
 ;;=^5139198
 ;;^UTILITY(U,$J,358.3,24686,0)
 ;;=R31.29^^107^1208^57
 ;;^UTILITY(U,$J,358.3,24686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24686,1,3,0)
 ;;=3^Hematuria,Microscopic,Other
 ;;^UTILITY(U,$J,358.3,24686,1,4,0)
 ;;=4^R31.29
 ;;^UTILITY(U,$J,358.3,24686,2)
 ;;=^5019327
 ;;^UTILITY(U,$J,358.3,24687,0)
 ;;=R39.198^^107^1208^70
 ;;^UTILITY(U,$J,358.3,24687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24687,1,3,0)
 ;;=3^Micturition,Oth Difficulties
 ;;^UTILITY(U,$J,358.3,24687,1,4,0)
 ;;=4^R39.198
 ;;^UTILITY(U,$J,358.3,24687,2)
 ;;=^5019347
 ;;^UTILITY(U,$J,358.3,24688,0)
 ;;=R39.191^^107^1208^72
 ;;^UTILITY(U,$J,358.3,24688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24688,1,3,0)
 ;;=3^Need to Immediately Re-Void
 ;;^UTILITY(U,$J,358.3,24688,1,4,0)
 ;;=4^R39.191
 ;;^UTILITY(U,$J,358.3,24688,2)
 ;;=^5139199
 ;;^UTILITY(U,$J,358.3,24689,0)
 ;;=R39.192^^107^1208^71
 ;;^UTILITY(U,$J,358.3,24689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24689,1,3,0)
 ;;=3^Micturition,Position Dependent
 ;;^UTILITY(U,$J,358.3,24689,1,4,0)
 ;;=4^R39.192
 ;;^UTILITY(U,$J,358.3,24689,2)
 ;;=^5139200
 ;;^UTILITY(U,$J,358.3,24690,0)
 ;;=R97.21^^107^1208^101
 ;;^UTILITY(U,$J,358.3,24690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24690,1,3,0)
 ;;=3^Rising PSA After Tx for Prostate CA
 ;;^UTILITY(U,$J,358.3,24690,1,4,0)
 ;;=4^R97.21
 ;;^UTILITY(U,$J,358.3,24690,2)
 ;;=^5139228
 ;;^UTILITY(U,$J,358.3,24691,0)
 ;;=N50.82^^107^1208^102
 ;;^UTILITY(U,$J,358.3,24691,1,0)
 ;;=^358.31IA^4^2
